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Background: Although the use of implantable cardioverter–deﬁbrillator/cardiac resynchronization ther-
apy device with a deﬁbrillator (ICD/CRT-D) is the principal therapy for patients with life-threatening
ventricular tachyarrhythmias/ventricular ﬁbrillation (VT/VF), prophylactic VT ablation may reduce
arrhythmic episodes and mortality in patients with an ICD/CRT-D. In this retrospective study, the
prognoses among patient groups with different results of attempted VT ablation were compared.
Methods: The study population consisted of 151 consecutive patients with an ICD/CRT-D and structural
heart disease. The mean age was 6479 years, and 63 of the 151 patients were women. Of the 151
patients, 117 cases underwent catheter ablation procedure for elimination of monomorphic VT. The 151
patients were divided into 3 groups based on the results of the ablation or whether ablation was
attempted, i.e., success, failure, and not-attempted groups (n¼87, 30, and 34, respectively). The event
rate of VT/VF and total mortality were compared among the 3 groups.
Results: During a follow-up period of 31722 months, VT/VF episodes and death occurred in 45 (30%)
and 16 (11%) patients, respectively. When comparing the 3 groups, the rates of VT/VF episodes and death
were signiﬁcantly lower in the success group than in the failure and not-attempted groups (16.1%, 46.7%,
50.0%, p¼0.0001 and 6.9%, 20.0%, 11.8%, p¼0.0213, respectively).
Conclusion: In patients with an ICD/CRT-D implant for VT/VF, prophylactic ablation of monomorphic VT
may reduce morbidity and mortality.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
The use of implantable deﬁbrillation devices such as an
implantable cardioverter–deﬁbrillator (ICD) or a cardiac resyn-
chronization therapy device with a deﬁbrillator (CRT-D) is the
primary therapy for improving prognoses of patients with life-
threatening ventricular tachyarrhythmias/ventricular ﬁbrillation
(VT/VF) [1]. In the Antiarrhythmics versus Implantable Deﬁbrilla-
tors (AVID) study, the superiority of deﬁbrillation therapy was
established by comparing prognoses of patients with ICD implan-
tation to that of those who received therapy with class III
antiarrhythmic agents such as amiodarone or sotalol for secondary
prevention of VT/VF [2]. In patients with implantable deﬁbrillation
devices, i.e., an ICD/CRT-D, additional preventive therapy for VT/VF
would not be required at least for reducing mortality, although
several reports have described the usefulness of preventive ther-
apy for reducing frequent deﬁbrillations [1–3]. Contrarily, severalt Rhythm Society. Published by Els
gy, Kitasato University School
mi-ku, Kanagawa 228-8555,
. Niwano).recent reports have documented the correlation between frequent
deﬁbrillation shocks and higher mortality in patients with a CRT-D
device and congestive heart failure [4]. In such reports, myocardial
damage caused by the frequent shocks has been considered the
reason for the poorer prognosis [5]; however, the frequent VT/VF
episodes may just be a surrogate marker for more serious under-
lying heart disease, which then determines the prognosis [6].
However, if the former hypothesis is correct, preventive therapy
for VT/VF may result in a better prognosis in patients with an ICD/
CRT-D. In the present study, we retrospectively analyzed the
patients who were implanted with a deﬁbrillation device, i.e., an
ICD/CRT-D, and compared their prognoses to those with and
without successful VT ablation in order to clarify the role of
preventive therapy in those patients.2. Methods
2.1. Patient population
The study population consisted of 151 consecutive patients
with an ICD/CRT-D and structural heart disease. Patients were
selected from the 252 consecutive patients who underwent ICD/evier B.V. All rights reserved.
Table 1
Clinical characteristics and outcomes in patients divided into groups according to different results on catheter ablation or whether the procedure was attempted.
Total Success Failure Not attempted p-value
Patients (n) 151 87 30 34
Age (years) 6479 6478 66 79 62711 0.1713
Gender (F:M) 63:88 40:47 10:20 13:21 0.4304
Underlying heart disease IHD 79, DCM 28, HCM 8,
VHD 29, CHD 4, Others 3
IHD 53, DCM 14, HCM 6,
VHD 9, CHD 4, Others 1
IHD 12, DCM 8, HCM 0,
VHD 9, CHD 0, Others 1
IHD 14, DCM 6, HCM 2,
VHD11, CHD 0, Others 1
0.1852
Device (ICD:CRT-D) 133:18 76:11 28:2 29:5 0.118
LVEF (%) 3077 3177 2975 3179 0.6843
Amiodarone (n) 51 (33.8%) 12 (13.8%) 15 (50.0%) 24 (70.6%) 0.0001n
Follow-up (months) 31722 35722 30721 23719 0.0846
VT/VF event (n) 45 (30%) 14 (16.1%) 14 (46.7%) 17 (50.0%) 0.0001n
Mortality (n) 16 (11%) 6 (6.9%) 6 (20.0%) 4 (11.8%) 0.0762
IHD, ischemic heart disease; DCM & HCM, dilated cardiomyopathy and hypertrophic cardiomyopathy; VHD, valvular heart disease; CHF, congenital heart disease; LVEF, left
ventricular ejection fraction.
n Indicates statistical signiﬁcance.
S. Niwano et al. / Journal of Arrhythmia 29 (2013) 338–341 339CRT-D implantation at our institute, and 101 patients with VF but
without structural heart disease were excluded, such as patients
with Brugada syndrome. The clinical characteristics of the patients
are summarized in Table 1. The mean age was 6479 years, and 63
of the 151 patients were women. The underlying heart diseases
were diagnosed on the basis of ﬁndings from cardiac catheteriza-
tion and echocardiography. The left ventricular ejection fraction
(LVEF) was determined using left ventriculography in 120 of the
151 patients and by echocardiography in the remaining 31
patients. All studies were performed with the approval of the
Clinical Studies and Ethics Committee of Kitasato University
Hospital.
2.2. Therapeutic procedure for the management of arrhythmias
Deﬁbrillation devices were indicated for previous VT/VF events
in 116 patients (ICD, 113 and CRT-D, 3) or inducible VT/VF in the
electrophysiologic study (EPS) in the remaining 35 patients (ICD,
20 and CRT-D, 15). A CRT device was indicated based on a widened
QRS interval (4150 ms) due to left branch block and left ven-
tricular dyssynchrony, which were ﬁndings in the echocardiogram
[7,8].
The EPS was performed with routine cardiac catheterization for
the diagnosis of underlying heart disease. The induction protocol
for VT/VF used a standard programmed electrical stimulation
protocol, i.e., 1–3 ventricular extra stimuli with 2 basic cycle
lengths (400 and 600 ms, routinely), burst-pacing with gradually
shortened ﬁxed cycle lengths (667–286 ms, routinely), and an
additional infusion of isoproterenol [9]. An evaluation of the
preventive effect of the antiarrhythmic agents using programmed
electrical stimulation, i.e., EPS-guided therapy, was not indicated
in any of the patients in this study population. The decision to use
of amiodarone was made empirically in individual patients based
on the appearance of ventricular arrhythmias or the history of the
deﬁbrillation device.
Catheter ablation was principally indicated for all electrocar-
diographically documented episodes of ventricular tachycardia
(VT) or for electrophysiologically inducible VT observed when
the QRS morphology was considered monomorphic; ablation
was not attempted in selected cases due to comorbid conditions
or patient refusal. When the ablation was performed after device
implantation, the ablation session was scheduled at least 2 months
after implantation to avoid any device problems associated with
the catheter-ablation procedure, such as a lead dislodgement. The
ﬁrst target of the VT ablation was set as the earliest endocardial
activation site during the VT. When the ablation of the earliest
activation site was ineffective, endocardial substrate mapping
using a CARTO systemwas performed, and a linear or area ablationwas performed when the arrhythmogenic substrate could be
determined. Epicardial ablation was not performed in this study
population. Catheter ablation was performed with a 4-mm-tip
ablation catheter in the temperature-control mode. An irrigation-
catheter system was used only in selected cases. The patients were
divided into 3 groups based on the results of the catheter ablation,
as follows: (1) Success group: after ablation, no VT/VF could be
induced after completion of the entire induction protocol; (2) Fail-
ure group: after ablation, one or more VT/VF morphologies
remained inducible; and (3) Not-attempted group: catheter abla-
tion was not attempted because of comorbid medical conditions or
patient refusal.
2.3. Observation protocol
After the ﬁnal therapy was determined, all patients were
followed for more than 6 months. During the follow-up period,
VT/VF events were identiﬁed and stored in the ICD/CRT-D devices.
The number of deaths was also recorded during the same follow-
up period. The event-free survival from VT/VF and the overall
survival were compared among the 3 groups with different results
of the catheter ablation, i.e., the success, failure, and not-
attempted groups.
2.4. Statistics
All values are expressed as the mean7standard deviation. The
statistical analyses were performed with a one-way ANOVA test
using JMP 10 statistical software (SAS Inc., Tokyo, Japan).
To compare the event rate among the groups, a chi-square test
and log-rank test were used to draw Kaplan–Meyer curves. A p-
value of o0.05 was considered signiﬁcant.3. Results
3.1. Results of the catheter ablation and grouping
Catheter ablation was attempted to eliminate 192 foci of
monomorphic VT in 117 of the 151 patients (mean foci per patient,
1.670.7), and ablation was not attempted in the remaining 34
patients due to comorbid VF in 23, severe heart failure in 7, and
patient refusal in 4. These patients comprised the “not-attempted”
group. The ablation session was performed before the device
implantation in 37 of the 117 patients and after the device
implantation in the remaining 80 patients. Even when ablation
was performed after the implant was in place, there were no
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Fig. 1. Event-free survival for VT/VF events. This ﬁgure exhibits the event-free
survival curves for patients with VT/VF in the 3 groups divided according to the
results after ablation for VT or whether they underwent the procedure. The event-
free survival for arrhythmic events was signiﬁcantly higher in the success group
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Fig. 2. Overall survival. This ﬁgure exhibits the survival curves for the total
mortality in the 3 groups with different results following the attempted ablation
of VT. The overall survival was signiﬁcantly higher in the success group than in the
other 2 groups. See text for details.
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ablation after implantation, ablation was planned to eliminate
the frequent episodes of VT caused by electrical storms. Out of 117
patients with documented and inducible VT who underwent an
ablation session, all of the episodes of VT became non-inducible in
87 patients and one or more episodes of VT remained inducible in
the remaining 30 patients; these were classiﬁed as “success” and
“failure” groups, respectively. There were no differences among the
3 groups in terms of the clinical background, except for the
incidence of amiodarone use (Table 1).
3.2. Follow-up and events
At least 6 months of follow-up was completed in all patients,
and the mean follow-up period was 31722 months. During the
follow-up period, death occurred in 16 of the 151 (11%) patients.
The cause of death was worsening heart failure in 13, malignancy
in other organs in 2, and a cerebral infarction in 1 patient. There
was no difference in the death rate among the 3 groups. During
the same follow-up period, VT/VF episodes were observed in 45 of
the 151 (30%) patients. There was a signiﬁcant difference in this
rate of arrhythmic events among the groups, with the rate of VT/
VF episodes being lower in the success group than in the other
3 groups (Table 1).
In the Kaplan–Meier curves, the event-free survival from VT/VF
was signiﬁcantly higher in the success group than in the other2 groups (Fig. 1). Additionally, the overall survival was higher in
the success group than in the other 2 groups (Fig. 2).4. Discussion
The present retrospective study, which evaluated the prog-
noses of patients with ICD/CRT-D and catheter ablation, revealed
several interesting ﬁndings. First, all documented or inducible
monomorphic VT could be successfully ablated in 87 of the 117
patients in whom catheter ablation was attempted. Second, no
serious problems with the implanted device, such as lead dis-
lodgement, occurred in any 80 of the 117 patients in whom
ablation was performed after device implantation. Third, when
comparing the patient groups with the different results of the
ablation, i.e., the success, failure, and not-attempted groups, there
was no signiﬁcant difference in clinical background, except for the
incidence of amiodarone use. Finally, when comparing the Kaplan–
Meier curves of these 3 groups, the morbidity, i.e., the rate of VT/
VF events, and mortality were signiﬁcantly lower in the success
group than in the other 2 groups.
4.1. Catheter ablation and deﬁbrillation devices
in patients with VT/VF
Both catheter ablation and deﬁbrillation device implants are
important non-pharmacological therapies in patients with life-
threatening ventricular arrhythmias [5,10]. From the point of view
of the therapeutic quality, catheter ablation may be superior, at
least for the purpose of achieving better patient quality of life
(QOL) because it is a preventive therapy. However, because the
success rate of catheter ablation for VT is limited [11], device
implantation should be considered superior for avoiding mortality.
The AVID study has clearly shown the superiority of cardioverter–
deﬁbrillator devices in comparison to preventive therapy, but the
preventative therapy in this trial was pharmacological therapy
using the class III antiarrhythmic agents, amiodarone and sotalol
[2]. In accordance with this agreement and recent guidelines [12],
we used a therapeutic strategy that placed device implantation as
the ﬁrst-line therapy in this retrospective observational study.
However, the addition of catheter ablation was not meaningless
and demonstrated a substantial beneﬁt, even in patients with prior
device implantation. Several reports have documented the beneﬁt
of catheter ablation in avoiding frequent episodes of VT after
electrical storms in cases of VT/VF with an ICD/CRT-D [13]; we
performed ablation sessions for this same clinical situation in 5 of
the 117 patients in whom we attempted catheter ablation.
When a catheter ablation is scheduled after device implanta-
tion, potential problems with the device, especially lead dislodge-
ments caused by the ablation procedure, should be avoided,
in particular, during the ablation of a right ventricular focus.
Conversely, the implanted lead might limit the control of the
ablation catheter; therefore, the order of the scheduling of the
therapeutic interventions is important. When the ablation had to
be performed after the device implantation, we scheduled the
session at least 2 months after the device implantation, and these
procedures did not cause any problems. Therefore, catheter abla-
tion can be considered a procedure that may be performed safely,
even in cases with a preceding device implantation.
4.2. Role of catheter ablation in patients with deﬁbrillation devices
Although life-threatening ventricular arrhythmias can be elimi-
nated by the action of implantable deﬁbrillation devices in
patients with VT/VF, frequent deﬁbrillation shocks will decrease
the patient’s QOL and may also result in shortening the battery life
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shock in cases with electrical storms, as described above.
In contrast, several reports have documented the relationship
between frequent deﬁbrillation shocks and a worse prognosis in
patients with left ventricular dysfunction [6]. The mechanism of
this relationship might be explained by hypothesizing that fre-
quent arrhythmias represent a more serious form of heart failure,
but another explanation might be that the frequent deﬁbrillation
shocks cause injury to the ventricular muscle [15]. If the latter
hypothesis correct, a reduction in arrhythmic events will lead to a
better prognosis in those patients with deﬁbrillation devices by
preventing myocardial injury. In the present study, we attempted
to eliminate monomorphic VT in 117 of the 151 cases with an
implanted deﬁbrillation device, and ablation was performed for
prophylactic purposes in at least 112 of the 117 cases. Thus, the
success group exhibited a lower rate of morbidity and mortality in
comparison to the failure and not-attempted groups. This result
corroborates a previous report [16]. Because the cause of death
included worsening heart failure in most (13/16) of the patients,
these results may indicate the preventive effect of a successful
ablation for cardiac mortality through the preservation of left
ventricular function.
However, because of the retrospective observational nature of
this study, the VT ablation attempts were not randomized, thus the
unsuccessful results, i.e., the failure or not-attempted groups, may
indicate a more complicated arrhythmogenic substrate. The suc-
cess group had the lowest incidence of amiodarone use compared
with all 3 groups (Table 1). Although the decision to use of
amiodarone depended partly on the result of ablation itself, the
reduced need for amiodarone in the success group may indicate
that this group may have initially included patients with a better
prognosis. Therefore, the unsuccessful results may play a role as
surrogate markers of more severe underlying heart disease. Reddy
et al. reported that prophylactic ablation would be effective in
reducing the morbidity, but not mortality, of patients in a study
designed as a randomized prospective study [17]. The difference
among the preceding reports and our present study may depend
on the difference in the study designs. The true effect of prophy-
lactic VT ablation in patients with deﬁbrillation devices should be
evaluated in a future study with a larger number of patients.5. Conclusions
We compared the prognoses of patients with ICD/CRT-D device
implants, among patient groups with different results of the
catheter ablation for VT. In the log-rank analysis, the patients with
a successful result of the VT ablation exhibited lower morbidity
and mortality in comparison to those with unsuccessful results, i.
e., the failure or not-attempted groups. Prophylactic ablation of
monomorphic VT may reduce the occurrence of morbidity and
mortality in patients with VT/VF and an ICD/CRT-D implantation.Conﬂict of Interest
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